Amanda Balbi

This Pediatrics FAQ page delivers concise, evidence-based answers to the clinical questions pediatricians and healthcare professionals are searching for right now. Drawing on the most recent US search trends and grounded in peer-reviewed literature, these summaries address common, high-impact pediatric concerns—from RSV and influenza management to measles exposure, community-acquired pneumonia, and norovirus outbreaks.

News Roctavian, an adeno-associated virus vector-based gene therapy, was approved by the US Food and Drug Administration (FDA) for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. This approval comes after a safety and effectiveness trial showed that Roctavian improved participants’ annualized bleeding rate after 3 years.

Clinical Insights The National Eczema Association estimates that 31.6 million individuals in the United States have some form of eczema.1 Patients report that itch, skin redness, and dryness are the most burdensome symptoms of disease, and 15% to 30% of patients with atopic dermatitis (AD) report sleep-related issues.1 With patients’ high level of disease burden comes an urgent need for novel treatment options.